Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) shares traded up 3.2% on Wednesday . The company traded as high as $11.92 and last traded at $11.90, with a volume of 81,686 shares trading hands. The stock had previously closed at $11.53.

A number of research analysts have weighed in on the stock. Zacks Investment Research cut shares of Sucampo Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 22nd. Roth Capital reiterated a “buy” rating on shares of Sucampo Pharmaceuticals in a research note on Wednesday, April 20th. Maxim Group reiterated a “buy” rating on shares of Sucampo Pharmaceuticals in a research note on Monday, July 11th. Mizuho reiterated a “buy” rating on shares of Sucampo Pharmaceuticals in a research note on Monday, July 11th. Finally, TheStreet cut shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 5th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Sucampo Pharmaceuticals has an average rating of “Buy” and an average price target of $21.00.

The stock has a market cap of $498.34 million and a price-to-earnings ratio of 23.15. The firm has a 50 day moving average price of $11.16 and a 200-day moving average price of $11.69.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.02. During the same quarter in the prior year, the business posted $0.14 earnings per share. The firm had revenue of $47.20 million for the quarter, compared to the consensus estimate of $44.11 million. The firm’s revenue for the quarter was up 60.0% compared to the same quarter last year. On average, equities research analysts forecast that Sucampo Pharmaceuticals Inc. will post $1.01 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Sucampo Pharmaceuticals stock. Systematic Financial Management LP boosted its position in shares of Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) by 18.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 101,745 shares of the biopharmaceutical company’s stock after buying an additional 15,590 shares during the period. Systematic Financial Management LP owned 0.23% of Sucampo Pharmaceuticals worth $1,759,000 at the end of the most recent quarter.

Sucampo Pharmaceuticals, Inc is a global biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders. It generates revenue from product royalties, development milestone payments, product sales and clinical development activities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.